Table 10 Summary of findings table for treatment with fremanezumab 675 mg quarterly subcutaneous injection compared with no treatment for prevention of episodic migraine

Reduction in migraine days follow up: 3 months

The mean reduction in migraine days was − 2.2 days

The mean reduction in migraine days in the intervention group was 1.3 days fewer (1.8 fewer to 0.7 fewer)

–

⨁⨁⨁◯MEDIUM^a

Treatment with fremanezumab 675 mg results in reduction in migraine days compared with placebo.

Reduction in use of acute attack medication follow up: 3 months

The mean reduction in use of acute attack medication was − 1.6 days

The mean reduction in use of acute attack medication in the intervention group was 1.3 days fewer (1.8 fewer to 0.8 fewer)

–

⨁⨁⨁◯MEDIUM^a

Treatment with fremanezumab 675 mg results in reduction in use of acute attack medication compared with placebo.

Improvement in functional MIDAS score follow up: 3 months

The mean improvement in functional MIDAS score was − 17.5 points

The mean improvement in functional MIDAS score in the intervention group was 5.4 points lower (8.9 lower to 1.9 lower)

–

⨁⨁⨁◯MEDIUM^a

Treatment with fremanezumab 675 mg results in improvement in functional MIDAS score compared with placebo.

At least 50% reduction in migraine days follow up: 3 months

279 per 1000

444 per 1000(355 to 557)

RR 1.5912

(1.2700 to 1.9937)

⨁⨁⨁◯MEDIUM^a

Treatment with fremanezumab 675 mg results in at least 50% reduction of days of migraine compared with placebo.

Serious adverse events follow up: 3 months

24 per 1000

10 per 1000(3 to 39)

RR 0.4330(0.1131 to 1.6582)

⨁⨁⨁◯MEDIUM^a

Treatment with fremanezumab 675 mg results in small possibly unimportant effect in serious adverse events occurrence compared with placebo.

Mortality follow up: 3 months

0 per 1000

< 1 per 1000(0 to 1)

RR 3.0308(0.1240 to 74.0995)

⨁⨁⨁◯MEDIUM^a

One death occurred in fremanezumab 675 mg group, and no deaths occurred in the placebo group during the double-blind treatment phase of the trials. Treatment with fremanezumab 675 mg results in small possibly unimportant effect in mortality compared with placebo.